Literature DB >> 8639426

Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders.

G Emilia1, C Messora, G Longo, M Bertesi.   

Abstract

We report on long-term treatment (13-62 months) with cyclosporin A (CyA) in eight patients with autoimmune haematological disorders, resistant to all usual therapies. Three patients had an autoimmune haemolytic anaemia (AHA); four an idiopathic thrombocytopenic purpura (ITP), and one an Evans syndrome. All patients were responsive: six achieved complete remission and two partial remission. The side-effects were moderate and transient. The majority of surviving patients remain dependent on continued drug administration. The CyA appears to be recommendable as a salvage treatment in life-threatening, resistant autoimmune haematological diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639426     DOI: 10.1046/j.1365-2141.1996.4871026.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

Review 3.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

Review 4.  Treatment of autoimmune hemolytic anemias.

Authors:  Alberto Zanella; Wilma Barcellini
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

5.  Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.

Authors:  Bruno Fattizzo; Silvia Cantoni; Juri Alessandro Giannotta; Laura Bandiera; Rachele Zavaglia; Marta Bortolotti; Wilma Barcellini
Journal:  Ther Adv Hematol       Date:  2022-05-14

6.  Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.

Authors:  Motohiro Kato; Katsuyoshi Koh; Akira Kikuchi; Ryoji Hanada
Journal:  Int J Hematol       Date:  2012-10-27       Impact factor: 2.490

7.  Clearance of pathological antibodies using biomimetic nanoparticles.

Authors:  Jonathan A Copp; Ronnie H Fang; Brian T Luk; Che-Ming J Hu; Weiwei Gao; Kang Zhang; Liangfang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

Review 8.  Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review.

Authors:  Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-08-10       Impact factor: 3.747

9.  High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

Authors:  Chae Young Kim; Eun Hye Lee; Hoi Soo Yoon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

Review 10.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.